Efficacy and Safety of Fast-Acting Insulin Aspart Are Maintained over 52 Weeks: Comparison with Insulin Aspart in Onset 1

被引：0
|
作者：
Mathieu, Chantal
Bode, Bruce W.
Franek, Edward
Philis-Tsimikas, Athena
Rose, Ludger
Graungaard, Tina
Osterskov, Anne Birk
Russell-Jones, David
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
992-P
引用
收藏
页码：A258 / A258
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of fast-acting insulin aspart are maintained over 52 weeks: Comparison with insulin aspart in onset 1
    Twigg, Stephen
    Mathieu, Chantal
    Bode, Bruce
    Franek, Edward
    Philis-Tsimikas, Athena
    Rose, Ludger
    Graungaard, Tina
    Osterskov, Anne Birk
    Russell-Jones, David
    [J]. CLINICAL ENDOCRINOLOGY, 2018, 89 : 63 - 63
  • [2] Efficacy and safety of fast-acting insulin aspart are maintained over 52 weeks: comparison with insulin aspart in onset 1
    Mathieu, C.
    Bode, B.
    Franek, E.
    Philis-Tsimikas, A.
    Rose, L.
    Graungaard, T.
    Osterskov, A.
    Russell-Jones, D.
    [J]. DIABETOLOGIA, 2017, 60 : S314 - S314
  • [3] ONSET 1: EFFICACY AND SAFETY OF MEALTIME FAST-ACTING INSULIN ASPART VERSUS INSULIN ASPART AFTER 52 WEEKS
    Bode, B.
    Mathieu, C.
    Franek, E.
    Philis-Tsimikas, A.
    Rose, L.
    Graungaard, T.
    Osterskov, A. B.
    Russell-Jones, D.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A29 - A29
  • [4] Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial
    Mathieu, Chantal
    Bode, Bruce W.
    Franek, Edward
    Philis-Tsimikas, Athena
    Rose, Ludger
    Graungaard, Tina
    Osterskov, Anne Birk
    Russell-Jones, David
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1148 - 1155
  • [5] Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan
    Kawamura, Tomoyuki
    Kikuchi, Toru
    Horio, Hiroshi
    Rathor, Naveen
    Ekelund, Magnus
    [J]. ENDOCRINE JOURNAL, 2021, 68 (04) : 409 - 420
  • [6] Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial
    Bode, Bruce W.
    Iotova, Violeta
    Kovarenko, Margarita
    Laffel, Lori M.
    Rao, Paturi V.
    Deenadayalan, Srikanth
    Ekelund, Magnus
    Larsen, Steffen Falgreen
    Danne, Thomas
    [J]. DIABETES CARE, 2019, 42 (07) : 1255 - 1262
  • [7] Efficacy and safety of fast-acting insulin aspart versus insulin aspart both in combination with insulin degludec with or without metformin in adults with diabetes
    Du, J.
    Wang, G. X.
    Wang, G.
    Liu, M.
    Thamattoor, U. K.
    Luan, Z. J.
    Alibegovic, A. C.
    Mu, Y. M.
    [J]. DIABETOLOGIA, 2023, 66 (SUPPL 1) : S377 - S377
  • [8] Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both with insulin degludec with or without metformin, in adults with type 2 diabetes
    Lane, W.
    Bozkurt, K.
    Favaro, E.
    Jang, H. C.
    Kjaersgaard, M. I. S.
    Oviedo, A.
    Rose, L.
    Senior, P.
    Sesti, G.
    Soto Gonzalez, A.
    Franek, E.
    [J]. DIABETOLOGIA, 2019, 62 : S10 - S11
  • [9] Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial
    Komatsu, Mitsuhisa
    Ekelund, Magnus
    Horio, Hiroshi
    Kadowaki, Takashi
    [J]. ENDOCRINE JOURNAL, 2021, 68 (04) : 429 - 440
  • [10] Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
    Marc Evans
    Mathew Wilkinson
    Angeliki Giannpolou
    [J]. Diabetes Therapy, 2019, 10 : 1793 - 1800
12345